MCM
ACAD icon

MAI Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

MAI Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-289
Closed -$6.43K – 2122
2026
Q1 		$6.43K Buy
289
+4
+1% +$96 ﹤0.01% 3381
2025
Q4 		$7.61K Buy
285
+185
+185% +$4.42K ﹤0.01% 2957
2025
Q3 		$2.13K Buy
+100
New +$2.37K ﹤0.01% 3297

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MAI Capital Management's ACAD Position: Q2 2026 in Review

MAI Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 289 shares — an estimated $6.43K sold.

MAI Capital Management first reported a position in ACAD in Q3 2025 and held it in 3 quarters. The position peaked at $7.61K in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • MAI Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 289 Acadia Pharmaceuticals shares in Q2 2026, an estimated $6.43K.
  • MAI Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • MAI Capital Management's Acadia Pharmaceuticals position peaked at $7.61K in Q4 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.